Repligen CORP Form 4 insider transactions

Repligen and BioLife provide supplemental disclosures regarding their merger, including details on executive compensation, ongoing litigation, and the upcoming BioLife stockholder meeting.

Jason K Garland, CFO of Repligen Corp, reported a transaction in 421 shares of common stock on September 25, 2026.

Olivier Loeillot, Chief Executive Officer and a Director of Repligen Corp, sold 5,426 shares of common stock on September 21, 2026 for $180.00 per share.

Repligen Corporation reports the expiration of the HSR waiting period for its acquisition of BioLife Solutions, Inc., moving closer to completion.

Olivier Loeillot, Chief Executive Officer and a Director of Repligen Corp, sold 3,035 shares of common stock on September 3, 2026 for $165.90 per share.

Violetta Hughes, CHIEF ACCOUNTING OFFICER of Repligen Corp, reported multiple transactions in common stock on March 5, 2026.

Olivier Loeillot, Chief Executive Officer and a Director of Repligen Corp, sold 5,426 shares of common stock on August 20, 2026 for $180.00 per share.

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, Inc. for a combination of cash and Repligen common stock, aiming to accelerate growth in the cell therapy market.

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, Inc. for approximately $1.5 billion in a cash and stock deal.

Jason K Garland, CFO of Repligen Corp, sold 530 shares of common stock on July 16, 2026 for $150.00 per share.

Repligen Corporation's CFO, Jason K. Garland, has sold shares of common stock as part of a pre-arranged trading plan.

Repligen Corporation Director Martin D. Madaus acquired 995 restricted stock units and was granted a stock option, as detailed in a Form 4 filing.

Konstantin Konstantinov, a Director at Repligen Corp, was awarded 995 restricted stock units on May 14, 2026.

Repligen Corporation Director Carrie Eglinton Manner acquired 995 restricted stock units and was granted a stock option to purchase 2,239 shares.

Repligen Corporation Director Glenn P. Muir exercised 2,434 stock options at a price of $38.76 per share.

Repligen Corporation Chief Product Officer Brian Douglass reported the withholding of 334 shares to satisfy tax obligations.

Repligen Corporation's CEO, Olivier Loeillot, has sold 3,832 shares of common stock for $140 per share as part of a pre-arranged 10b5-1 trading plan.

Repligen Corporation's Senior VP of R&D, Ralf Kuriyel, received grants of 5,284 restricted stock units and 5,669 stock options.

Repligen Corporation's CEO, Olivier Loeillot, received significant equity awards, including restricted stock units and stock options, enhancing his ownership stake.

Repligen Corporation's Chief Operating Officer, James Bylund, was granted 7,751 restricted stock units and 8,315 stock options.

Repligen Corporation's CFO, Jason K. Garland, received an award of restricted stock units and stock options as part of his compensation.

Repligen's Chief Operating Officer, James Bylund, reported the acquisition of shares from a performance stock unit award and the subsequent disposition of shares for tax withholding.

Repligen's Senior VP of R&D, Ralf Kuriyel, increased his direct beneficial ownership by 83 shares following the vesting of performance stock units and tax withholding.

Repligen's Chief Operating Officer, James Bylund, disposed of common stock to cover tax liabilities related to restricted stock unit vesting.

Repligen CEO Olivier Loeillot disposed of common stock shares to cover tax withholding obligations related to restricted stock unit releases.

A Repligen Corporation director disposed of 9,897 common shares to cover tax obligations from restricted stock unit vesting.

Repligen Corporation's CFO, Jason K. Garland, reported the disposition of shares to cover tax obligations related to restricted stock unit releases.

Repligen's Senior VP of R&D, Ralf Kuriyel, reported the disposition of shares to cover tax liabilities arising from restricted stock unit vesting.

Repligen's Chief Product Officer, Brian Robb Douglass, disposed of 221 shares of common stock to cover tax withholding obligations.

Repligen's Chief Product Officer, Brian Robb Douglass, was granted 2,288 restricted stock units and 2,143 stock options, vesting over three years.